Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

View:
Post by WarrantOfficer on Nov 23, 2020 6:41pm

Zero Volume

COVID hit in March, summertime historically slow for the markets, zero press releases with  content to raise awareness, bank balance down to last 15K a while ago, financing coming with a possible share dilution, strategic business plan being remodelled. Iodine properties in limbo, long wait on Health Canada approval, political circus in the USA and Canada COVID cases reaching an all time high. The perfect storm so to speak. In conclusion, currently very little to spark investment interest. .

On a positive note the updated PEA makes the Francis Creek resource worth about 800M. The next few NR will set in motion where the company is heading.
Comment by postie1 on Nov 24, 2020 4:25pm
Is the inground value not worth more than the share price, much more?
Comment by WarrantOfficer on Nov 25, 2020 8:26am
A few mining valuation techniques. Mining Valuation Techniques - P/NAV, P/CF, EV/Resource (corporatefinanceinstitute.com)  Public sentiment plays a large part also. I sent you a DM postie1..
Comment by postie1 on Nov 25, 2020 8:23pm
The wait  for HCis not helping public sentiment!  Replied, hope I was of some help.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1